Indian trials of the Sputnik-V vaccine candidate, being developed by Russia#39;s sovereign wealth fund, will enroll 1,000-2,000 participants and be conducted at multiple government and private hospitals across the country, Deepak Sapra, CEO for API and pharmaceutical services at Dr. Reddy#39;s, told Reuters.India trials for Russia#39;s #39;Sputnik-V#39; vaccine may begin in next few weeks: Dr Reddy#39;s
Indian trials of the Sputnik-V vaccine candidate, being developed by Russia#39;s sovereign wealth fund, will enroll 1,000-2,000 participants and be conducted at multiple government and private hospitals across the country, Deepak Sapra, CEO for API and pharmaceutical services at Dr. Reddy#39;s, told Reuters.
Subscribe to:
Post Comments (Atom)
-
The company, one of the leading manufacturers of soda ash, had initiated the process of carving out its textiles business into GHCL Textile...
-
The BRLLR linked to RBI Repo Rate is revised downwards in line with the reduction on Reserve Bank of India Repo Rate from 5.15 percent to 4...
-
The company did not export units last month while it had dispatched 804 Etios units in in June 2019.
No comments:
Post a Comment